Cambridge, Mass. – September 13, 2026 -- Marengo Therapeutics has completed enrollment in the monotherapy cohorts of its Phase 1/2 STARt-001 trial evaluating invikafusp alfa across eight distinct PD-1-resistant tumor types, with updated results selected for an oral presentation at the ESMO 2026 Congress in Madrid, October 23-27.

San Francisco – September 13, 2026 -- Cionic reported that the first 60 participants in its TRANSFORM study showed an average 26% improvement in health-related quality of life after one month, using the standardized EQ-5D-5L instrument across all five measured dimensions.

South San Francisco, Calif. – September 12, 2026 -- IDEAYA Biosciences and Servier have dosed the first patient in OptimUM-11, a global Phase 3 trial testing darovasertib combined with crizotinib as adjuvant therapy for primary uveal melanoma, targeting a disease segment with no approved systemic treatment options.

Shanghai – September 11, 2026 -- CorrectSequence Therapeutics (Correctseq) reported that its transformer Base Editor (tBE) therapy CS-101/CS-206 achieved full transfusion independence or elimination of vaso-occlusive crises (VOC) in four new patients from Nigeria, Laos, Malaysia and Pakistan, expanding on earlier results in five Chinese patients who all reached transfusion independence.

San Diego – September 09, 2026 -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) will webcast primary endpoint results from the randomized, controlled Phase 2 portion of its HexAgon study on Tuesday, September 8, 2026 at 5:00 a.m. Pacific Time.

Carlsbad – September 08, 2026 -- Tyra Biosciences, Inc. (Nasdaq: TYRA) will disclose initial clinical results from its SURF302 Phase 2 study of oral dabogratinib in intermediate risk non-muscle invasive bladder cancer (IR NMIBC) during a conference call scheduled for September 9, 2026, at 8:00 am ET.

Valby, Denmark – September 07, 2026 -- Lundbeck will present preclinical data at the European Epilepsy Congress in Athens showing its investigational drug bexicaserin simultaneously increases inhibitory and decreases excitatory neuronal activity in hippocampal brain tissue, a dual mechanism the company says supports broad-spectrum antiseizure potential across multiple epilepsy types.

CARY, N.C. -- September 01, 2026 -- Veloxis Pharmaceuticals dosed the first participant on Aug. 31, 2026, in its Phase 2 RENGEVITY-201 trial testing pegrizeprument, an investigational immunosuppressive drug, against tacrolimus in kidney transplant recipients. The Cary, North Carolina-based company, a unit of Asahi Kasei Corporation, will enroll up to 120 de novo kidney transplant patients across multiple sites in the randomized, partially blinded study registered as NCT07290777.